STOCK TITAN

Alkermes (ALKS) 6.1% stake reported by Baker Bros. group

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Baker Bros. Advisors LP and related entities filed a Schedule 13G reporting beneficial ownership of 10,012,267 Alkermes plc ordinary shares, equal to 6.1% of the class, based on 165,117,509 shares outstanding as of October 24, 2025.

The shares are held through two investment funds: 667, L.P. with 845,828 shares (0.5%) and Baker Brothers Life Sciences, L.P. with 9,166,439 shares (5.6%). The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Alkermes.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Baker Bros. Advisors LP
Signature:/s/ Scott L. Lessing
Name/Title:Scott L. Lessing/ President By: Baker Bros. Advisors (GP) LLC, its general partner
Date:02/17/2026
Baker Bros. Advisors (GP) LLC
Signature:/s/ Scott L. Lessing
Name/Title:Scott L. Lessing/ President
Date:02/17/2026
Julian C. Baker
Signature:/s/ Julian C. Baker
Name/Title:Julian C. Baker
Date:02/17/2026
Felix J. Baker
Signature:/s/ Felix J. Baker
Name/Title:Felix J. Baker
Date:02/17/2026
Exhibit Information

EXHIBIT 99.1 Joint Filing Agreement

Alkermes Plc

NASDAQ:ALKS

ALKS Rankings

ALKS Latest News

ALKS Latest SEC Filings

ALKS Stock Data

5.32B
161.80M
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
Ireland
DUBLIN 4